After Mylan announced it would resume producing chloroquine, shares rose dramatically. Anecdotal evidence suggests the anti-malaria drug as a possible COVID-19 cure. Shortages of chloroquine in the U.S. have been reported. Shares of Mylan (NASDAQ:MYL) received a boost after the biotech firm announced that it would resume manufacturing hydroxychloroquine-sulfate tablets. The anti-malaria drug has been…